Table 1. Descriptive analysis of PLWH included in our study with and without SARS-CoV-2 infection.
| Study population (N = 3567) | SARS-CoV-2 negative (N = 2531) | SARS-CoV-2 positive (N = 1036) | p-value | |||||
|---|---|---|---|---|---|---|---|---|
| Sex | 0,064 | |||||||
| Male | 2758 | 77,3% | 1978 | 71,7% | 780 | 28,3% | ||
| Female | 809 | 22,7% | 553 | 68,4% | 256 | 31,6% | ||
| Age, years | <0,005 | |||||||
| median (IQR) | 51 | (44–59) | 52 | (45–59) | 49 | (41–57) | ||
| <35 | 336 | 9,4% | 196 | 58,3% | 140 | 41,7% | ||
| 36–50 | 1260 | 35,3% | 844 | 67,7% | 416 | 33,0% | ||
| 51–65 | 1666 | 46,7% | 1248 | 74,9% | 418 | 25,1% | ||
| 66–80 | 277 | 7,8% | 220 | 79,4% | 57 | 20,6% | ||
| 80–95 | 27 | 0,8% | 22 | 81,5% | 5 | 18,5% | ||
| missing | 1 | 0,0% | 1 | |||||
| Origin | <0,005 | |||||||
| Europe | 2930 | 82,1% | 2095 | 71,5% | 835 | 28,5% | ||
| Africa | 117 | 3,3% | 95 | 81,2% | 22 | 18,8% | ||
| South America | 493 | 13,8% | 317 | 64,3% | 176 | 35,7% | ||
| Others | 27 | 0,8% | 24 | 88,9% | 3 | 11,1% | ||
| HIV transmission route | <0,001 | |||||||
| HTX | 1121 | 31,4% | 816 | 72,8% | 305 | 27,2% | ||
| IDU | 747 | 20,9% | 562 | 75,2% | 185 | 24,8% | ||
| MSM | 1484 | 41,6% | 999 | 67,3% | 485 | 32,7% | ||
| others | 50 | 1,4% | 32 | 64,0% | 18 | 36,0% | ||
| unknown | 165 | 4,6% | 122 | 73,9% | 43 | 26,1% | ||
| Tobacco use | 0,515 | |||||||
| Smoker | 1190 | 33,4% | 859 | 72,2% | 331 | 27,8% | ||
| Ex-smoker | 530 | 14,9% | 374 | 70,6% | 156 | 29,4% | ||
| Non-smoker | 1847 | 51,78 | 1298 | 70,3% | 549 | 29,7% | ||
| CDC clinical category | 0,001 | |||||||
| Category A | 2259 | 63,3% | 1561 | 69,1% | 698 | 30,9% | ||
| Category B / C | 1308 | 36,7% | 970 | 74,2% | 338 | 25,8% | ||
| Years since HIV diagnosis | 14,6 | (7,5–24,3) | 15,3 | (8,3–24,9) | 13 | (6,4–22,4) | <0,005 | |
| CD4 nadir | 274 | (131–427) | 267 | (124–416) | 297 | (161–466) | <0,005 | |
| CD4 cell count before infection or end of study period (cells per uL) | 0,079 | |||||||
| median (IQR) | 783 | (550–1061) | 777 | (540–1051) | 794 | (567–1078) | ||
| <200 | 100 | 2,82% | 71 | 71,0% | 29 | 29% | ||
| 200–349 | 240 | 6,76% | 181 | 75,4% | 59 | 24,6% | ||
| 350–500 | 384 | 10,82% | 290 | 75.5% | 94 | 24,5% | ||
| >500 | 2825 | 79,60% | 1985 | 70,3% | 840 | 29,7% | ||
| CD4/CD8 before infection or end of study period | 0,301 | |||||||
| median (IQR) | 0,84 | (0,56–1,18) | 0,84 | (0,54–1,18) | 0,84 | (0,59–1,2) | ||
| <0.8 | 1528 | 42,8% | 1124 | 73,6% | 404 | 26,4% | ||
| 0.8–1 | 571 | 16,0% | 432 | 75,7% | 139 | 24,3% | ||
| >1 | 1238 | 34,7% | 894 | 72,2% | 344 | 27,8% | ||
| missig | 230 | 6,4% | 81 | 35,21% | 149 | 64,78% | ||
| VL>50 before infection or end of study period | 0,981 | |||||||
| No | 3328 | 93,3% | 2371 | 71,2% | 957 | 28,8% | ||
| Yes | 222 | 6,2% | 158 | 71,2% | 64 | 28,8% | ||
| missing | 17 | 0,5% | 2 | 11,8% | 15 | 88,2% | ||
| VL detectable at any point during the study period | 0,45 | |||||||
| No | 2899 | 81,3% | 2065 | 71,2% | 834 | 28,8% | ||
| Yes | 668 | 18,7% | 466 | 69,8% | 202 | 30,2% | ||
| Tenofovir-based regimen | 0,608 | |||||||
| No | 1350 | 37,8% | 963 | 71,3% | 387 | 28,7% | ||
| yes | 2168 | 60,8% | 1529 | 70,5% | 639 | 29,5% | ||
| missing | 49 | 1,4% | 39 | 79,6% | 10 | 20,4% | ||
| Vaccionation regimen before infection or end of study period | 0,001 | |||||||
| Unvaccinated or incomplete | 1103 | 30,9% | 488 | 44,2% | 615 | 55,8% | ||
| Complete | 1002 | 28,1% | 690 | 68,9% | 312 | 31,1% | ||
| Booster | 1462 | 41,0% | 1353 | 92,5% | 109 | 7,5% | ||
| Modified Charlson Index | <0,005 | |||||||
| 0–1 | 2368 | 66,4% | 1626 | 68,7% | 742 | 31,3% | ||
| 2–3 | 354 | 9,9% | 261 | 73,7% | 93 | 26,3% | ||
| >3 | 845 | 23,7% | 644 | 76,2% | 201 | 23,8% | ||
| Chronic comorbidities | ||||||||
| Hypertension | 487 | 13,7% | 378 | 77,6% | 109 | 22,4% | <0,005 | |
| Dyslipidaemia | 460 | 12,9% | 344 | 74,8% | 116 | 25,2% | 0,053 | |
| Obesity | 566 | 15,9% | 399 | 70,5% | 167 | 29,5% | 0,792 | |
| Chronic obstructive pulmonary disease | 384 | 10,8% | 271 | 70,6% | 113 | 29,4% | 0,861 | |
| HCV infection | 695 | 19,5% | 520 | 74,8% | 175 | 25,2% | 0,012 | |
| Chronic kidney disease | 223 | 6,3% | 176 | 78,9% | 47 | 21,1% | 0,007 | |
| Chronic ischaemic heart disease | 60 | 1,7% | 45 | 75,0% | 15 | 25,0% | 0,486 | |
| Diabetes | 321 | 9% | 203 | 71,7% | 91 | 28,3% | 0,774 | |
HTX = heterosexual. IDU = injecting drug user. CDC clinical category for VIH symptoms. Catergory A = asymptomatic. Categroy B/C = Symptomatic. MSM = men who have sex with men. VL = viral load. P-value for categorical variables referes to chi-square test, and for continuous variables to the Mann-Whitney U test.